Vertex Pharmaceuticals
(NASDAQ) VRTX
Vertex Pharmaceuticals Financials at a Glance
Market Cap
$107.94B
Revenue (TTM)
$12.26B
Net Income (TTM)
$4.34B
EPS (TTM)
$16.86
P/E Ratio
25.16
Dividend
$0.00
Beta (Volatility)
0.58 (Low)
Dividend
$0.00
Beta (Volatility)
0.58 (Low)
Price
$427.48
Volume
1,203,285.727
Open
$422.67
Price
$427.48
Volume
1,203,285.727
Open
$422.67
Previous Close
$427.65
Daily Range
$422.67 - $431.06
52-Week Range
$362.50 - $507.92
Dividend
$0.00
Beta (Volatility)
0.58 (Low)
Price
$427.48
Volume
1,203,285.727
Open
$422.67
Previous Close
$427.65
Daily Range
$422.67 - $431.06
52-Week Range
$362.50 - $507.92
VRTX News
Best Biotech ETFs to Buy in 2026
VRTX: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Vertex Pharmaceuticals
Industry
Biotechnology
Sector
Health CareEmployees
6,400
CEO
Reshma Kewalramani, MD
Website
www.vrtx.comHeadquarters
Boston, MA 02210, US
VRTX Financials
Key Financial Metrics (TTM)
Gross Margin
86%
Operating Margin
39%
Net Income Margin
35%
Return on Equity
24%
Return on Capital
21%
Return on Assets
16%
Earnings Yield
3.97%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$107.94B
Shares Outstanding
254.36M
Volume
1.20M
Avg. Volume
1.37M
Financials (TTM)
Gross Profit
$10.27B
Operating Income
$4.76B
EBITDA
$4.97B
Operating Cash Flow
$3.63B
Capital Expenditure
$437.60M
Free Cash Flow
$3.19B
Cash & ST Invst.
$6.61B
Total Debt
$3.88B
Vertex Pharmaceuticals Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$2.99B
+7.8%
Gross Profit
$2.59B
+7.8%
Gross Margin
86.85%
N/A
Market Cap
$107.94B
N/A
Market Cap/Employee
$17.70M
N/A
Employees
6,100
N/A
Net Income
$1.03B
+59.6%
EBITDA
$1.14B
+45.6%
Quarterly Fundamentals
Net Cash
$5.26B
+15.6%
Accounts Receivable
$2.00B
+10.6%
Inventory
$1.77B
+29.9%
Long Term Debt
$1.99B
+20.5%
Short Term Debt
$0.00
N/A
Return on Assets
16.38%
N/A
Return on Invested Capital
21.13%
N/A
Free Cash Flow
$1.29B
+66.4%
Operating Cash Flow
$1.43B
+74.4%